Development and pilot testing of a decision aid for men considering genetic testing for breast and/or ovarian cancer-related mutations (BRCA1/2)
- PMID: 19072564
- DOI: 10.1089/gte.2008.0035
Development and pilot testing of a decision aid for men considering genetic testing for breast and/or ovarian cancer-related mutations (BRCA1/2)
Abstract
Despite the fact that both men and women can carry a breast/ovarian cancer-related mutation, the main emphasis in genetic counseling for breast/ovarian cancer-related risk remains on females. This study aimed to develop and pilot a decision aid specifically designed for men with a strong family history of breast and/or ovarian cancer who are considering genetic testing. The decision aid was developed by a multidisciplinary team of experts and a consumer representative. It was then reviewed by 27 men who had previously undergone genetic testing to identify a mutation in a BRCA1 or BRCA2 gene. All men who reviewed the decision aid indicated that they would recommend the booklet to other men in the same situation, and 96% of the sample (n = 26) reported being "very satisfied" or "satisfied" with the information contained in the decision aid. The decision aid was perceived by all participants as "very relevant" or "quite relevant" for men considering genetic testing. Ninety-three percent of men felt that it was easy to weigh the pros and cons of genetic testing with the help of the decision aid. The perceived impact on participants' emotions and understanding of the genetic testing process was also assessed. Several factors may hinder men from effectively weighing up the potential benefits and risks of genetic testing. A greater understanding of these issues may help health professionals to encourage men with a strong family history of breast and/or ovarian cancer to learn about cancer risk and the appropriate management strategies for themselves and their female relatives.
Similar articles
-
Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation.Clin Genet. 2007 Sep;72(3):208-17. doi: 10.1111/j.1399-0004.2007.00859.x. Clin Genet. 2007. PMID: 17718858
-
Factors associated with an individual's decision to withdraw from genetic testing for breast and ovarian cancer susceptibility: implications for counseling.Genet Test. 2007 Spring;11(1):45-54. doi: 10.1089/gte.2006.9998. Genet Test. 2007. PMID: 17394392
-
A randomized trial of a breast/ovarian cancer genetic testing decision aid used as a communication aid during genetic counseling.Psychooncology. 2008 Aug;17(8):844-54. doi: 10.1002/pon.1353. Psychooncology. 2008. PMID: 18613319 Clinical Trial.
-
The pros and cons of genetic testing for breast and ovarian cancer risk.Int J Fertil Womens Med. 1999 May-Jun;44(3):139-45. Int J Fertil Womens Med. 1999. PMID: 10435912 Review.
-
Familial breast and ovarian cancers.Int J Clin Oncol. 2004 Aug;9(4):270-82. doi: 10.1007/s10147-004-0423-3. Int J Clin Oncol. 2004. PMID: 15375703 Review.
Cited by
-
On the development of a decision support intervention for mothers undergoing BRCA1/2 cancer genetic testing regarding communicating test results to their children.Fam Cancer. 2010 Mar;9(1):89-97. doi: 10.1007/s10689-009-9267-3. Epub 2009 Jul 17. Fam Cancer. 2010. PMID: 19609726 Free PMC article.
-
BRCA1/2 genetic testing uptake and psychosocial outcomes in men.Fam Cancer. 2011 Jun;10(2):213-23. doi: 10.1007/s10689-011-9425-2. Fam Cancer. 2011. PMID: 21365268 Free PMC article.
-
The Genetic Education for Men (GEM) Trial: Development of Web-Based Education for Untested Men in BRCA1/2-Positive Families.J Cancer Educ. 2021 Feb;36(1):72-84. doi: 10.1007/s13187-019-01599-y. J Cancer Educ. 2021. PMID: 31402434 Free PMC article. Clinical Trial.
-
Psychological Determinants of Men's Adherence to Cascade Screening for BRCA1/2.Curr Oncol. 2022 Apr 2;29(4):2490-2503. doi: 10.3390/curroncol29040203. Curr Oncol. 2022. PMID: 35448177 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous